Cynosure will snatch up Palomar Medical Technologies for $294 million in cash and stock, in a deal that brings some intriguing consolidation to the cosmetic laser industry.
Earlier this month, Radiant Research exited the CRO business, as parent company Clinical Research Advantage shipped out its drug development arm. Now the company is focusing on its remaining core business: maintaining and expanding a network of clinical trial sites.
Two private equity firms are pooling their CRO resources, agreeing to merge the formerly public BioClinica with imaging and cardiac safety contractor CoreLab.
Now that Mylan has agreed to buy Strides Arcolab's injectables unit for $1.6 billion, analysts are seeing potential injectable drug deals on every corner.
Stryker is buying up a number of VertiFlex's spinal surgery implants and technologies for an undisclosed price.
Life Technologies is getting a close look from a bevy of private equity giants, but analysts warn that the company isn't growing fast enough to convince would-be buyers to pony up the rumored $15.7 billion asking price.
Johnson & Johnson's Cordis has snatched up a New Jersey maker of self-expanding, flexible stents, with the idea of expanding its own offerings in the technology to treat peripheral artery disease.
The cancer drug developer's shares have risen more than 50% in 2013 as the company begins late-stage development of its lead drug neratinib for patients with metastatic HER2-positive breast cancer.
Shire's new CEO apprentice has closed on his first buyout deal for the company. Flemming Ornskov took the lead this morning in announcing that Shire has snapped up the Swedish biotech Premacure AB in a deal that will add a near late-stage, rare disease program to the company's bustling Human Genetic Therapies group in Lexington, MA.
Lexington, MA-based Cubist Pharmaceuticals has bought out Astellas' rights to ceftolozane, putting up $25 million in cash for an antibiotic that has demonstrated some promising outcomes in clinical studies.